A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT ID: NCT00399906
Last Updated: 2015-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
99 participants
INTERVENTIONAL
2007-08-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1
10 mg
BMS-582949
Tablets, Oral, Once daily, 12 weeks
A2
30 mg
BMS-582949
Tablets, Oral, Once daily, 12 weeks
A3
100 mg
BMS-582949
Tablets, Oral, Once daily, 12 weeks
P1
10 or 100 mg
Placebo
Tablets, Oral, Once daily, 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-582949
Tablets, Oral, Once daily, 12 weeks
Placebo
Tablets, Oral, Once daily, 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-75 years of age
* Diagnosis of moderate to severe psoriasis for at least six months at the time of screening
* Subjects will require wash-out of certain therapies for the treatment of psoriasis but will be allowed to continue on certain topical therapies
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Kogarah, New South Wales, Australia
Local Institution
Greenslopes, Queensland, Australia
Local Institution
North Adelaide, South Australia, Australia
Local Institution
Carlton, Victoria, Australia
Local Institution
Malvern, Victoria, Australia
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Surrey, British Columbia, Canada
Local Institution
Winnipeg, Manitoba, Canada
Local Institution
St. John's, Newfoundland and Labrador, Canada
Local Institution
Halifax, Nova Scotia, Canada
Local Institution
Oakville, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Waterloo, Ontario, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Québec, Quebec, Canada
Local Institution
Saint-Léonard, Quebec, Canada
Local Institution
México, Aguascalientes, Mexico
Local Institution
Zapopan, Jalisco, Mexico
Local Institution
Df, Mexico City, Mexico
Local Institution
Monterrey, Nuevo León, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Investigator Inquiry form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM119-013
Identifier Type: -
Identifier Source: org_study_id